IGIV 10% (intravenous immunoglobulin)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for IGIV 10% (intravenous immunoglobulin), covering 2026-04-14 to 2026-04-14. Get the full timeline:
Most recent: Clinical Trial Update: A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [Phase 3]